nvax fda news - Search News

Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold

Shares of Novavax NVAX lost nearly 20% on Wednesday after the company announced that the FDA has placed a clinical hold on its experimental COVID-19-Influenza Combination (“CIC”) and stand-alone influenza vaccine candidates.

biopharma-reporter · 2h

FDA places hold on Novavax’s COVID and influenza vaccine

A report of a case of motor neuropathy in a patient who received the vaccine last year has led the FDA to halt its development while more information is gathered.

MarketWatch on MSN · 2h

Novavax’s stock slides 19% after FDA puts clinical hold on COVID and flu vaccine candidates

Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu vaccine candidates, following a case of motor neuropathy in a participant in a mid-stage trial.

The Pharma Letter1h

FDA slaps CRL on Novavax' COVID-19 flu combo trial IND

Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

23h

FDA Puts Speed Breaker On Novavax's COVID/Flu Combo Shot Trial On Concerns Related To Damaged Nerves

Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s ...

Hosted on MSN17h

Novavax (NASDAQ:NVAX) Stock Drops 18% after Clinical Trial Is Halted

Shares of pharmaceutical company Novavax ($NVAX) are down 18% on news that the U.S. Food and Drug Administration (FDA) has ...

45m

Novavax’s Regulatory Setback and Mid-Term Underperformance: An Analyst’s Perspective

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

Novavax Stock Falls Nearly 20% After Clinical Trial Halted

Shares of American pharmaceutical company Novavax (NVAX) fell 19% on reports that the U.S. Food and Drug Administration (FDA) ...

SchaeffersResearch.com20h

3 Vaccine Stocks to Watch as Flu Season Approaches

Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...

Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

(Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M(TM) adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on Novavax ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results